摘要
[目的]研究新型血清标志物Monototal在非小细胞肺癌诊断中的临床应用价值。[方法]选取197例非小细胞肺癌患者、35例肺部良性疾病患者和120例健康体检血清标本,检测CA125、CEA、CYFRA21-1、SCC和Monototal水平。采用SPSS 19.0进行统计分析,比较不同血清肿瘤标志物诊断非小细胞肺癌的敏感度和特异性。[结果]非小细胞肺癌组血清Monototal中位浓度是53.19U/L,显著性高于肺部良性组(41.60U/L)和健康体检组(5.55U/L)(P均<0.01)。血清Monototal诊断非小细胞肺癌的敏感度(30.46%)和特异性(91.43%)与Cyfra21-l(38.07%,94.29%)较为接近。不同临床分期中,Monototal诊断Ⅰ期肺癌的敏感度最高,为19.05%,Cyfra21-1则为17.86%。Cyfra21-1诊断Ⅱ、Ⅲ、Ⅳ期肺癌的敏感度最高,分别为46.51%、61.90%和75.00%;而Monototal则分别为30.23%、50.00%和41.67%。[结论 ]Monototal是一种较好的非小细胞肺癌肿瘤标志物,对非小细胞肺癌的诊断效能接近Cyfra21-1,对早期非小细胞肺癌辅助诊断可能有更好的诊断价值。
[Purpose] To investigate the clinical significance of serum novel cytokeratin biomarker montotal for diagnosis of non-small cell lung cancer（NSCLC）. [Methods] 197 cases of patients with non-small cell lung cancer,35 cases with benign lung disease and 120 healthy volunteers from Cancer Hospital, Chinese Academy of Medical Science were enrolled in this study. The serum level of CA125,CEA,Cyfra21-1 SCC and Monototal was detected. Sensitivity and specificity of several tumor markers for diagnosis of NSCLC was analyzed by SPSS 19.0. [Results] The median of serum Monototal in NSCLC group was 53.19U/L,which was significantly higher than that in benign lung disease patients（41.60U/L） and healthy volunteers（5.55U/L）（P〈0.01）. The sensitivity and specificity of Monototal for NSCLC were 30.46% and 91.43% respectively,which were closed to that of Cyfra21-1 with sensitivity and specificity of 38.07% and 94.29% respectively. The sensitivity of Monototal for NSCLC stage Ⅰ was the highest with a sensitivity of 19.05%,and that of Cyfra21-1 was 17.86%. The sensitivity of Cyfra21-1 for stage Ⅱ , Ⅲ, Ⅳ was 46.51%,61.90% and 75.00% respectively,and that of Monototal was 30.23% ,50.00% and 41.67% respectively. [Conclusion] Monototal might be a good tumor marker for NSCLC,Whose diagnostic value is closed to Cyfra21-1. In respect of sensitivity and specificity for non-small cell lung cancer（NSCLC）, Monototal might have a better diagnostic value in diagnosis for earlv stage non-small cell lung cancer.
出处
《中国肿瘤》
CAS
2015年第5期426-429,共4页
China Cancer
基金
北京希望马拉松专项基金资助项目(LC2012A05)
